Executive Responsible for Commercializing Multiple Drugs
BETHESDA,
MD (SharewellNewswire.com) September 18, 2012 - Northwest
Biotherapeutics (OTC.BB: NWBO) (NW Bio), a biotechnology company
developing DCVax® personalized immune therapies for cancer, announced
today that it has appointed former pharmaceutical industry executive
Dr. Günter Rosskamp as the CEO of the Company’s German subsidiary,
Northwest Biotherapeutics, Gmbh.
Dr. Rosskamp brings extensive
experience as a senior manager in the pharmaceutical sector.
He previously served as Head of Central Nervous System (CNS)
therapeutics at Schering AG (now part of Bayer AG) with responsibility
for research and development, and global marketing and sales, of CNS
products. This included such drugs as Dopergin (for Parkinson’s
disease) and Noctamide (a sleeping aid).
Dr.
Rosskamp also served as Project Leader for the development and
registration (product approval) of the blockbuster drug, Betaseron (for
multiple sclerosis), in the European Union.
He
subsequently served as Head of Strategic Business Development at
Schering AG reporting directly to the Board and determining suitable
opportunities in existing franchise areas of the Company, such as
hormone products and diagnostics, and new franchise areas such
CNS therapeutics and cardiology.
Dr. Rosskamp also
served as Vice President of Life Sciences and Chemicals at the
German Industrial Investment Council (IIC). In that role, he developed
a broad network throughout the global pharmaceutical and life sciences
industry, including in the US and Asia as well as in Europe.
Dr.
Rosskamp served as CEO of three biotech companies, including a company
developing treatments for inflammatory and immune disorders, and two
companies developing cell therapy products. Dr. Rosskamp’s experience
with clinical trials and regulatory requirements for such cellular
products will be particularly useful for NW Bio.
“NW
Bio’s DCVax technology is one of the most exciting technologies I have
seen in my career,” commented Dr. Rosskamp, “and NW Bio has made
impressive progress in their lead program for brain cancer in both the
US and Europe, and in building a deep pipeline of additional
applications and product lines. I am very pleased to join NW Bio and
help with the ongoing clinical development, and the registration and
commercialization of their DCVax products.”
“We
are excited to have Dr. Rosskamp, a widely respected industry veteran,
join our Team,” commented Linda Powers, CEO of NW Bio. “Dr. Rosskamp’s
wealth of experience with physicians, regulators and industry
throughout the German and European pharma and biotech sectors, will
provide a strategic advantage in building NW Bio’s operations in
Europe.”
Dr. Rosskamp succeeds Dr. Bernhard Faber,
who served as the interim start-up CEO of NW Bio’s German subsidiary,
and who also manages the Bioville, Gmbh consulting firm. “We
appreciate Dr. Faber’s helpful role in the initial establishment and
launch of our German subsidiary,” said Linda Powers. “Dr. Faber made
an important contribution to our German program.”
For further information about the Company and its programs, please visit the Company’s website at
www.nwbio.com.
About Northwest Biotherapeutics
Northwest
Biotherapeutics is a biotechnology company focused on developing
immunotherapy products to treat cancers more effectively than current
treatments, without toxicities of the kind associated with
chemotherapies, and on a cost-effective basis, in both the United
States and Europe. The Company has a broad platform technology for
DCVax® dendritic cell-based vaccines. The Company’s lead program is a
300-patient Phase III trial in newly diagnosed Glioblastoma multiforme
(GBM). GBM is the most aggressive and lethal brain cancer. The Company
also previously received clearance from the FDA for a 612-patient Phase
III trial in prostate cancer, and clearance from the FDA for Phase I/II
trials in multiple other cancers.
The Company has also conducted a
Phase I/II trial with DCVax® for metastatic ovarian cancer.
Disclaimer
Statements
made in this news release that are not historical facts, including
statements concerning future treatment of patients with GBM using
DCVax® and future clinical trials, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “expect,” “believe,” “intend,” "plan," "continue,"
"may," "will," "anticipate," and similar expressions are intended to
identify forward-looking statements. Actual results may
differ materially from those projected in any forward-looking
statement. Specifically, there are a number of important factors that
could cause actual results to differ materially from those anticipated,
such as the Company’s ability to raise additional capital, risks
related to the Company’s ability to enroll patients in its clinical
trials and complete the trials on a timely basis, the uncertainty of
the clinical trials process, uncertainties about the timely performance
of third parties, and whether the Company’s products will demonstrate
safety and efficacy. Additional information on these and other
factors, including Risk Factors, which could affect the
Company’s results, is included in its Securities and Exchange
Commission (“SEC”) filings. Finally, there may be other factors not
mentioned above or included in the Company’s SEC filings that may cause
actual results to differ materially from those projected in any
forward-looking statement. You should not place undue reliance on any
forward-looking statements. The Company assumes no obligation to
update any forward-looking statements as a result of new information,
future events or developments, except as required by securities laws.
###
Contact Info:Les Goldman 202-841-7909
lgoldman@nwbio.comBeverly Jedynak ( 312-943-1123 )
http://www.nwbio.comNorthwest Biotherapeutics
Source : Northwest Biotherapeutics Appoints Pharma Industry Veteran As Ceo Of German Subsidiary(SharewellNewswire.com)
